TD Private Client Wealth LLC Buys 1,607 Shares of Becton, Dickinson and Company (NYSE:BDX)

TD Private Client Wealth LLC boosted its position in Becton, Dickinson and Company (NYSE:BDX - Free Report) by 44.6% in the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 5,210 shares of the medical instruments supplier's stock after purchasing an additional 1,607 shares during the period. TD Private Client Wealth LLC's holdings in Becton, Dickinson and Company were worth $1,193,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also bought and sold shares of the company. Smallwood Wealth Investment Management LLC acquired a new position in Becton, Dickinson and Company in the 1st quarter worth about $27,000. Alpine Bank Wealth Management acquired a new position in Becton, Dickinson and Company in the 1st quarter worth about $29,000. REAP Financial Group LLC increased its holdings in Becton, Dickinson and Company by 75.3% in the 4th quarter. REAP Financial Group LLC now owns 128 shares of the medical instruments supplier's stock worth $29,000 after purchasing an additional 55 shares in the last quarter. Picton Mahoney Asset Management increased its holdings in Becton, Dickinson and Company by 61.4% in the 4th quarter. Picton Mahoney Asset Management now owns 142 shares of the medical instruments supplier's stock worth $32,000 after purchasing an additional 54 shares in the last quarter. Finally, Nexus Investment Management ULC acquired a new position in Becton, Dickinson and Company in the 1st quarter worth about $34,000. Institutional investors and hedge funds own 86.97% of the company's stock.

Insider Transactions at Becton, Dickinson and Company

In other news, EVP David Shan sold 1,166 shares of the business's stock in a transaction dated Monday, June 2nd. The stock was sold at an average price of $171.19, for a total value of $199,607.54. Following the completion of the sale, the executive vice president owned 4,575 shares of the company's stock, valued at approximately $783,194.25. The trade was a 20.31% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. 0.36% of the stock is currently owned by company insiders.

Becton, Dickinson and Company Stock Performance

NYSE:BDX traded up $2.77 during trading hours on Thursday, reaching $178.27. The stock had a trading volume of 745,786 shares, compared to its average volume of 2,556,537. The stock has a market cap of $51.09 billion, a P/E ratio of 34.03, a price-to-earnings-growth ratio of 1.32 and a beta of 0.25. Becton, Dickinson and Company has a 12-month low of $163.33 and a 12-month high of $251.99. The company has a debt-to-equity ratio of 0.70, a quick ratio of 0.64 and a current ratio of 1.13. The stock has a 50 day simple moving average of $172.03 and a 200 day simple moving average of $206.75.

Becton, Dickinson and Company (NYSE:BDX - Get Free Report) last posted its quarterly earnings data on Thursday, May 1st. The medical instruments supplier reported $3.35 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.28 by $0.07. The company had revenue of $5.27 billion during the quarter, compared to analyst estimates of $5.35 billion. Becton, Dickinson and Company had a return on equity of 15.99% and a net margin of 7.28%. The firm's quarterly revenue was up 4.5% on a year-over-year basis. During the same quarter last year, the company earned $3.17 earnings per share. On average, research analysts forecast that Becton, Dickinson and Company will post 14.43 EPS for the current fiscal year.

Becton, Dickinson and Company Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Monday, June 30th. Shareholders of record on Monday, June 9th were paid a dividend of $1.04 per share. This represents a $4.16 annualized dividend and a yield of 2.33%. The ex-dividend date of this dividend was Monday, June 9th. Becton, Dickinson and Company's dividend payout ratio (DPR) is currently 79.39%.

Wall Street Analyst Weigh In

Several brokerages have recently weighed in on BDX. Piper Sandler cut Becton, Dickinson and Company from an "overweight" rating to a "neutral" rating and decreased their price target for the company from $260.00 to $185.00 in a research note on Friday, May 2nd. Citigroup lowered Becton, Dickinson and Company from a "strong-buy" rating to a "hold" rating and cut their price target for the stock from $217.00 to $185.00 in a report on Thursday, May 22nd. William Blair lowered Becton, Dickinson and Company from an "outperform" rating to a "market perform" rating in a report on Thursday, May 1st. Wall Street Zen lowered Becton, Dickinson and Company from a "buy" rating to a "hold" rating in a report on Friday, May 2nd. Finally, Stifel Nicolaus decreased their price target on Becton, Dickinson and Company from $280.00 to $224.00 and set a "buy" rating for the company in a research report on Friday, May 2nd. Eight investment analysts have rated the stock with a hold rating and four have issued a buy rating to the company's stock. According to MarketBeat.com, the stock presently has an average rating of "Hold" and an average price target of $219.22.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.